Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C35H52O9 |
Molecular Weight | 616.782 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 14 / 14 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@]2([C@H](C)CC(=O)[C@@H]1OC1(C)C)C(=O)C[C@@]3(C)C4=CC[C@]5([H])[C@]6(C[C@@]46[C@@H](O)C[C@]23C)CC[C@H](O[C@]7([H])OC[C@@H](O)[C@H](O)[C@H]7O)C5(C)C
InChI
InChIKey=PYBFXJMIKJNNAJ-GLWILYKISA-N
InChI=1S/C35H52O9/c1-17(12-18(36)28-31(4,5)44-28)25-19(37)13-32(6)22-9-8-21-30(2,3)24(43-29-27(41)26(40)20(38)15-42-29)10-11-34(21)16-35(22,34)23(39)14-33(25,32)7/h9,17,20-21,23-29,38-41H,8,10-16H2,1-7H3/t17-,20-,21+,23+,24+,25+,26+,27-,28+,29+,32+,33-,34-,35+/m1/s1
Cimicifugoside H1 is biogenetically key compounds of Cimicifugae Rhizoma. In China, the rhizomes of C. foetida L. are used to treat some symptoms, such as headache, toothache, mouth ulcers, and sore throat. Cimicifugoside H1 is a major constituent of Cimicifuga foetida L. extract with 23-epi-26-deoxyactein, cimigenolxyloside, and 25-O-acetylcimigenoside present at lower levels (the percentage 21.2%, 1.6%, 2.9% and 1.1%) but systemic exposure to 23-epi-26-deoxyactein, cimigenolxyloside, and 25-O-acetylcimigenoside following oral administration of the extract of Cimicifuga foetida L. was significantly greater than to Cimicifugoside H1. The low oral bioavailability of Cimicifugoside H1 is probably the result of its poor membrane permeability leading to poor intestinal absorption.
Originator
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Studies on the Chinese crude drug "shoma." IX. Three novel cyclolanostanol xylosides, cimicifugosides H-1, H-2 and H-5, from cimicifuga rhizome. | 1995 May |
|
[Chemical constituents of original plants of Cimicifugae rhizoma in Chinese medicine]. | 1996 Nov |
|
Cycloartane triterpene saponins from the roots of Cimicifuga foetida. | 2001 May |
|
Triterpenoid glycoside from Cimicifuga racemosa. | 2005 Oct |
|
[Cycloartane triterpenoid of Cimicifuga foetida]. | 2009 Aug |
|
Simultaneous determination of cimicifugoside H-2, cimicifugoside H-1, 23-epi-26-deoxyactein, cimigenol xyloside and 25-O-acetylcimigenoside in beagle dog plasma by LC-MS/MS. | 2012 Mar 25 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22771280
Rat: 5mg/kg
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16176901
Inhibitory activities of cimicifugoside H-1 against Shigella flexneri, Shigella dysenteriae, Shigella sonnei, Mycobacterium tuberculosis, a-hemolytic Streptococcus and Streptococcus pneumoniae was determined by the paper disk diffusion assay on agar plates. The samples were dissolved in chloroform and applied to a paper disk with a syringe (500 mg each disk), respectively. The disks were dried with flow air and put onto agar media inoculated with the testing organism. Inhibition zones were observed after incubation for 10 h at 428C. Cimicifugoside H-1 hasn’t antibacterial activity in the agar diffusion assay.
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
163046-73-9
Created by
admin on Sat Dec 16 08:17:43 GMT 2023 , Edited by admin on Sat Dec 16 08:17:43 GMT 2023
|
PRIMARY | |||
|
15241163
Created by
admin on Sat Dec 16 08:17:43 GMT 2023 , Edited by admin on Sat Dec 16 08:17:43 GMT 2023
|
PRIMARY | |||
|
C3LF0ZYD3S
Created by
admin on Sat Dec 16 08:17:43 GMT 2023 , Edited by admin on Sat Dec 16 08:17:43 GMT 2023
|
PRIMARY |
SUBSTANCE RECORD